199 related articles for article (PubMed ID: 35671249)
21. Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
Kawahata W; Asami T; Kiyoi T; Irie T; Kashimoto S; Furuichi H; Sawa M
J Med Chem; 2021 Oct; 64(19):14129-14141. PubMed ID: 34529443
[TBL] [Abstract][Full Text] [Related]
22. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies.
Robbins DW; Noviski MA; Tan YS; Konst ZA; Kelly A; Auger P; Brathaban N; Cass R; Chan ML; Cherala G; Clifton MC; Gajewski S; Ingallinera TG; Karr D; Kato D; Ma J; McKinnell J; McIntosh J; Mihalic J; Murphy B; Panga JR; Peng G; Powers J; Perez L; Rountree R; Tenn-McClellan A; Sands AT; Weiss DR; Wu J; Ye J; Guiducci C; Hansen G; Cohen F
J Med Chem; 2024 Feb; 67(4):2321-2336. PubMed ID: 38300987
[TBL] [Abstract][Full Text] [Related]
23. PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding.
Tinworth CP; Lithgow H; Dittus L; Bassi ZI; Hughes SE; Muelbaier M; Dai H; Smith IED; Kerr WJ; Burley GA; Bantscheff M; Harling JD
ACS Chem Biol; 2019 Mar; 14(3):342-347. PubMed ID: 30807093
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
[TBL] [Abstract][Full Text] [Related]
25. Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models.
Lim YS; Yoo SM; Patil V; Kim HW; Kim HH; Suh B; Park JY; Jeong NR; Park CH; Ryu JH; Lee BH; Kim P; Lee SH
Blood Adv; 2023 Jan; 7(1):92-105. PubMed ID: 36269842
[TBL] [Abstract][Full Text] [Related]
26. Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.
Shorer Arbel Y; Katz BZ; Gabizon R; Shraga A; Bronstein Y; Kamdjou T; Globerson Levin A; Perry C; Avivi I; London N; Herishanu Y
Front Oncol; 2021; 11():646971. PubMed ID: 34055615
[TBL] [Abstract][Full Text] [Related]
27. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
Yang M; Jiang H; Yang Z; Liu X; Sun H; Hao M; Hu J; Chen X; Jin J; Wang X
Eur J Med Chem; 2022 Nov; 241():114611. PubMed ID: 35939993
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological evaluation of novel pyrazolo-pyrimidin-amines as potent and selective BTK inhibitors.
Joshi D; Bahekar R; Soman S; Jadav P; Patel D; Goswami A; Pethani J; Kumar J; Patel J; Sundar R; Goswami P; Goshdastidar K; Patel H; Patel A; Bandyopadhyay D; Chattarjee A; Sharma M; Jain M; Desai R
Bioorg Chem; 2023 Jan; 130():106238. PubMed ID: 36403335
[TBL] [Abstract][Full Text] [Related]
30. Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
Dou D; Sha W; Diao Y; Su R; Qiao Y; Yu Z; Zhao Z; Li H; Chen Z; Xu Y
Bioorg Chem; 2022 Feb; 119():105541. PubMed ID: 34910982
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton's Tyrosine Kinase via Molecular Dynamics Simulations.
Yu X; Qiu S; Sun D; Guo P; Li Q
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364276
[TBL] [Abstract][Full Text] [Related]
32. Discovery of pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
Su R; Diao Y; Sha W; Dou D; Yu Z; Leng L; Zhao Z; Chen Z; Li H; Xu Y
Bioorg Chem; 2022 Sep; 126():105860. PubMed ID: 35661525
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Ibrutinib-based BTK PROTACs with in vivo anti-inflammatory efficacy by inhibiting NF-κB activation.
Huang J; Ma Z; Yang Z; He Z; Bao J; Peng X; Liu Y; Chen T; Cai S; Chen J; Zeng Z
Eur J Med Chem; 2023 Nov; 259():115664. PubMed ID: 37487306
[TBL] [Abstract][Full Text] [Related]
34. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
[TBL] [Abstract][Full Text] [Related]
35. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase.
Zhang D; Xu G; Zhao J; Wang Y; Wu X; He X; Li W; Zhang S; Yang S; Ma C; Jiang Y; Ding Q
Eur J Med Chem; 2021 Dec; 225():113724. PubMed ID: 34391034
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling.
Mera WA; Alzihlif M; Taha MO; Khanfar MA
Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297
[TBL] [Abstract][Full Text] [Related]
38. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
39. BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma.
Yuan H; Zhu Y; Cheng Y; Hou J; Jin F; Li M; Jia W; Cheng Z; Xing H; Liu M; Han T
J Biol Chem; 2022 Nov; 298(11):102555. PubMed ID: 36183831
[TBL] [Abstract][Full Text] [Related]
40. Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
Xue Y; Song P; Song Z; Wang A; Tong L; Geng M; Ding J; Liu Q; Sun L; Xie H; Zhang A
J Med Chem; 2018 May; 61(10):4608-4627. PubMed ID: 29715023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
